Myocardial Stunning Clinical Trial
Official title:
Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial
This study aims to confirm the safety and efficacy of diazoxide as an additive to hyperkalemic cardioplegia in patients undergoing cardiac surgery with cardiopulmonary bypass. The investigators hypothesize that diazoxide combined with hyperkalemic cardioplegia provides superior myocardial protection and reduced myocardial stunning compared with standard cardioplegia alone. Thirty patients will receive treatment. Safety will be assessed by comparing mean arterial blood pressure measurements, glucose levels and incidence of adverse events between the two groups. Efficacy will be assessed by comparing right and left ventricular function in pre-operative vs post-operative transesophageal echocardiograms, need for mechanical circulatory support, ease of separation from bypass and Vasoactive Inotrope Score (VIS) between the two groups. The information gained could pave the way for the use of Katp (Potassium-atp) channel openers to prevent stunning, improve patient outcomes, and reduce health care costs related to myocardial stunning that requires inotropic and mechanical support following cardiac surgery.
This is a Phase I clinical trial. Thirty patients total will receive treatment (IV Diazoxide added to cardioplegia). Diazoxide will be added to the first dose of cardioplegia only. Subsequent doses of cardioplegia will not contain additives. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04830982 -
Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
|
Phase 1 | |
| Completed |
NCT00213746 -
Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)
|
N/A | |
| Active, not recruiting |
NCT00123695 -
Serial Echocardiography After Subarachnoid Hemorrhage
|
N/A | |
| Terminated |
NCT01500785 -
Intracoronary Administration of Levosimendan in Cardiac Surgery Patients
|
Phase 4 | |
| Completed |
NCT06450912 -
Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
|
||
| Completed |
NCT02545426 -
Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration
|
N/A | |
| Completed |
NCT01179802 -
Exercise-induced Changes in Cardiac Function & Morphology
|
N/A | |
| Recruiting |
NCT04448639 -
Stunning in Takotsubo Versus Acute Myocardial Infarction
|
||
| Withdrawn |
NCT02770183 -
Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation.
|
||
| Recruiting |
NCT05669144 -
Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05209230 -
Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients?
|
N/A | |
| Withdrawn |
NCT02687269 -
Ranolazine a Potential New Therapeutic Application
|
Phase 4 |